Welcome to our dedicated page for Scilex Holding news (Ticker: SCLX), a resource for investors and traders seeking the latest updates and insights on Scilex Holding stock.
Scilex Holding Company reports developments tied to its non-opioid pain management business, pharmaceutical assets and related healthcare investments. The company acquires, develops and commercializes products for acute and chronic pain, including ZTlido for postherpetic neuralgia, ELYXYB for acute migraine treatment in adults and Gloperba for prophylaxis of gout flares in adults.
Recurring Scilex news also includes material agreements, capital-structure actions, shareholder distributions involving Dream Bowl tokens, intellectual property and litigation counsel matters, strategic investments, clinical or regulatory disclosures, governance updates and operating and financial results.
Scilex Holding Company (Nasdaq: SCLX) has officially launched ELYXYBTM, the only FDA-approved oral solution for the acute treatment of migraines in adults. With an estimated U.S. oral migraine drug market size of $1.8 billion in 2022, the company sees significant revenue potential. The re-launch strategies include over 6,000 engagements with potential customers and multiple promotional efforts. Scilex is negotiating a distribution agreement for ELYXYBTM and has a specialized sales force targeting over 80% of physicians. This product diversifies Scilex's pain management portfolio and enhances cash flow and earnings through non-opioid solutions.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced that the U.S. Bankruptcy Court granted interim approval for $75 million debtor-in-possession financing from JMB Capital Partners as part of its Chapter 11 proceedings initiated on February 13, 2023. This financing ensures continued business operations, including employee wages. Sorrento possesses approximately $1 billion in assets but sought Chapter 11 to protect its business from litigation risks. Meanwhile, Scilex Holding Company (Nasdaq: SCLX), Sorrento's majority-owned subsidiary, is not affected by the bankruptcy, continuing its focus on non-opioid pain management products.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced the U.S. Bankruptcy Court approved its employee wages motion and interim cash management motion following its Chapter 11 filing on February 13, 2023. This approval allows the company to maintain normal operations while safeguarding its business, which includes over $1 billion in assets. Sorrento aims to protect stakeholder value amid ongoing litigation. Notably, Scilex Holding Company (Nasdaq: SCLX), a majority-owned subsidiary, remains unaffected by Sorrento's bankruptcy and continues to operate and develop non-opioid pain management products.
Sorrento Therapeutics announced on February 16, 2023, that the U.S. Bankruptcy Court for the Southern District of Texas approved its motions for employee wages and interim cash management, following its Chapter 11 petition filed on February 13, 2023. The company, which has over $1 billion in assets, seeks to protect its business amidst litigation risks. Scilex Holding Company, a majority-owned subsidiary, is not a debtor in this process and continues its operations focusing on innovative pain management products. CEO Henry Ji stated that these motions will help maintain normal operations and support the development of new therapies.